Panacea Biotec Surges 7% As FDA Clears Solan Facility
Shares of Panacea Biotec surged as much as 6.76 per cent to hit intraday high of Rs 112.80 in an otherwise weak market after the US drug regulator (USFDA) gave its Establishment Inspection... Panacea Biotec Ltd. Announces Receipt of Establishment Inspection Report (EIR) from USFDA
Panacea Biotec Ltd has informed BSE regarding a Press Release dated November 21, 2016 titled "Panacea Biotec Ltd. Announces Receipt of Establishment Inspection Report (EIR) from USFDA". Updates
With reference to the earlier letter dated November 15, 2016, Panacea Biotec Ltd has submitted to BSE a copy of the notice for the attention of equity shareholders of the Company in respect of proposed transfer of equity shares of the Company to Investor Education and Protection Fund Suspense Account, published on November 14, 2016 in Newspaper, in accordance with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and refund) Rules, 2016. Updates
Panacea Biotec Ltd has submitted to BSE a copy of the notice for the attention of equity shareholders of the Company in respect of proposed transfer of equity shares of the Company to Investor Education and Protection Fund Suspense Account, published on 14th November, 2016 in the newspapers, in accordance with Rule 6 of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and refund) Rules, 2016. Standalone Financial Results, Limited Review Report for September 30, 2016
Panacea Biotec Ltd has informed BSE about : 1. Standalone Financial Results for the period ended September 30, 20162. Standalone Limited Review for the period ended September 30, 2016 Board Meeting Intimation for Results & Closure of Trading Window
Panacea Biotec Ltd has informed BSE that a Meeting of the Board of Directors of the Company is scheduled to be held on November 11, 2016, inter alia, to consider and approve the Unaudited Financial Results (Provisional) for the quarter and half year ended September 30, 2016.Further, pursuant to the provisions of Regulations 30 & 51 of the SEBI (LODR) Regulations, the trading window of the Company shall remain closed for all designated persons... Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended September 30, 2016
Panacea Biotec Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended September 30, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Shareholding for the Period Ended September 30, 2016
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2016. For more details, kindly Click here Disclosure of Voting results of AGM (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Panacea Biotec Ltd has informed BSE regarding the details of Voting results at the Annual General Meeting (AGM) of the Company held on September 28, 2016, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report. Non-availability of D-penicillamine disrupts Panacea Biotec's Cilamin capsule supply
The company, which recently released limited quantities of the medicine in the market, is holding talks with Indian and China raw material suppliers to normalise the situation